Member Info for nottsbaggie

For those who don't use Twitter....

Added ~1m to #N4P last week, and glad to have following today’s news.

Another package of grant funding and access to nanoparticle experts across the continent.

Nuvec has the potential to be revolutionary to DNA/RNA vaccine delivery. The industry sees this; AIM doesn’t - yet!

8:29 AM - 24 Sep 2018

Recent news doesn't seem to have stopped Myles adding. A million added last week.

https://twitter.com/AIM_Chaos/status/1044126621710643200

I assume we will get another TR1 then as the last one was back in January when he notified his 5% holding.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=N4P&ArticleCode=haaueva0&ArticleHeadline=Holdings_in_Company

Bob, I like "You're not singing anymore, you're not singing anymore"

Be quite appropriate for a few individuals that pop up on here!

P.S. He mentions that one of the offtakers are currently onsite checking on construction progress.

Michael Masterman, chairman of W Resources PLC (LON:WRES), skyped into the Proactive studio from onsite at La Parrilla in Spain to update on construction.

http://www.proactiveinvestors.co.uk/companies/stocktube/10446/w-resources-plc-on-site-at-la-parilla-in-spain-as-construction-advances

Of course, according to sum its all a figment of our imagination!

Sorry, should have said "first of 3".

Yes and just posted another update on Twitter.

A short video. Today at LP, installation of the first 3 Metso crushers.

https://twitter.com/WResourcesPlc/status/1035496776541691904

Great to see!

https://twitter.com/WResourcesPlc/status/1035364360908992513

https://twitter.com/WResourcesPlc/status/1035360720018264064

I'm with you Geng. Surely it has to be the Hansource shares.

The last update on this was May 3rd when MM stated they were trying to get the company reinstated.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=WRES&ArticleCode=iwvezro6&ArticleHeadline=Hansource_Investments_Limited

Well the company was dissolved in June 2016 so it is likely too much time has passed to be able to do this.It is interesting that the 3 million sales started only a few weeks after the above RNS which suggests to me it is likely to be the case.

About time MM gave us an update on this as 3 months have now passed.

As for the people that set up Hansource, they are a bunch of bloody amateurs!

Given up on this one.

Sold my holding today and put the entire proceeds into MTR. Hopefully that will recoup my losses here.

GLA.

Some positive news....

https://www.asx.com.au/asxpdf/20180810/pdf/43x73qh6zdxv00.pdf

SO what.

When was that? April?

Since then we have invested in KML and now will want to progress KEMCO.

Things evolve. I am happy MTR are making the right decisions to increase shareholder value over time.

T

I have just noticed my 400k buy around 12:06 is showing as a sell as it was a fraction below mid price at the time.

Been here since 2015.

Added another 400k around 2.85 and then 200k around 2.87.

Thanks to the market for allowing me to buy just above the 2.8 placing price. Never look a gift horse in the mouth!

Plenty of newsflow to come. Onwards and upwards!

Link.....

https://www.asx.com.au/asxpdf/20180806/pdf/43x39fs20v6d6l.pdf

https://twitter.com/AIM_Chaos/status/1016275136083841024

https://aimchaos.files.wordpress.com/2018/06/n4p-update-note-14-06-2018.pdf

From the mentioned page 3....

It is also important to note that were the Phase I trial to be unsuccessful, that would not be a major
concern for the Company. As the CEO stated in the RNS of 18 April:
“The data gathered from the Trial will enable the Company to establish whether its reformulation has
been sufficiently successful to allow N4 Pharma to prepare for a pre-IND meeting with the FDA towards
the end of this year or whether further amendments to the reformulation may be required to optimise
efficacy.”
The properties of sildenafil are not being trialled, but simply the method of ingestion and whether it
enhances the properties of the drug specifically for treating ED, in comparison to Viagra. If the trial is
unsuccessful, then another Phase I trial will be rescheduled at a cost we estimate would be circa
£0.50m, with the physical makeup of the drug being tweaked. Of course, as the AIM market is
primarily driven by retail investors (sentiment and short termism regularly trump rational
valuations), N4P’s share price would in all probability take a severe hit if it were it deemed necessary
the Phase I trial had to be re-run. For longer term investors, this would permit an excellent
investment opportunity.

Hi Troajan, yes that works.

They have also done another tweet in the last 10-15 mins which now links to that youtube video.

Strange. Maybe, they edited some stuff out. This one seems a bit short.

Proactive tweeted this around quarter to 9 this morning....

https://twitter.com/proactive_UK/status/1012240050220945408

However, this interview with MM has now been removed. Did anyone manage to watch it before it disappeared? It suggests maybe MM gave out some info which he shouldn't have or was incorrect or misleading?

Resolutions... https://www.ascentresources.co.uk/wp-content/uploads/2018/05/NOM_2018-06-18_Final.pdf

https://twitter.com/Shareless1/status/1008662144852856833 All passed except number 6.